MARSHALL WACE, LLP

Position in SPRY — ARS Pharmaceuticals, Inc.

CIK 1318757 LONDON, X0

Position in SPRY

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$990,948

+$147,751 QoQ

Shares Held

123,714

+17.8% QoQ

Ownership

0.124%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#55

of 208 holders

Holding Since

Sep 2021

12 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. SPRY ranks #181 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	543,897	$270,169,956
2	INCY	Incyte Corp	1,310,154	$148,519,056
3	RPRX	Royalty Pharma plc	2,450,669	$137,409,009
4	SYRE	Spyre Therapeutics, Inc.	991,693	$88,042,503
5	ALNY	Alnylam Pharmaceuticals, Inc.	259,799	$78,207,292
6	TVTX	Travere Therapeutics, Inc.	1,333,207	$75,739,488
7	MANE	Veradermics, Inc	585,560	$71,988,746
8	DFTX	Definium Therapeutics, Inc.	1,298,946	$61,102,419

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$990,948	123,714	+17.8%	Shares	Other	2026-08-13
2026-03-31	$843,197	105,006	+32.6%	Shares	Other	2026-05-15
2025-12-31	$922,843	79,214	-59.9%	Shares	Other	2026-02-13
2025-09-30	$1,983,065	197,320	+394.4%	Shares	Other	2025-11-13
2025-06-30	$696,498	39,914	-74.5%	Shares	Other	2025-08-13
2025-03-31	$1,970,467	156,635	+196.1%	Shares	Other	2025-05-15
2024-12-31	$558,157	52,906	-32.1%	Shares	Other	2025-02-13
2024-09-30	$1,129,245	77,879	+4.4%	Shares	Other	2024-11-14
2023-06-30	$499,960	74,621	+89.3%	Shares	Other	2023-08-14
2023-03-31	$256,676	39,428	+23.2%	Shares	Other	2023-05-15
2022-12-31	$273,053	32,011	-88.4%	Shares	Other	2023-02-14
2021-09-30	$2,750,158	275,567	—	Shares	Sole	2021-11-15
No filing history on record for this holder in this stock.